Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)
Phase 3
Completed
- Conditions
- Macular DegenerationMaculopathy, Age-RelatedAge-Related MaculopathiesAge-Related MaculopathyMaculopathies, Age-Related
- Interventions
- Other: Anecortave Acetate Vehicle
- Registration Number
- NCT00051129
- Lead Sponsor
- Alcon Research
- Brief Summary
The purpose of this study was to evaluate anecortave acetate compared to placebo for maintenance of visual acuity after 24 months of treatment in patients with subfovial choroidal neovascularization (CNV) due to exudative age-related macular degeneration (AMD).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 291
Inclusion Criteria
- Diagnosis of exudative AMD and a primary or recurrent subfoveal CNV lesion in the study eye.
- Other protocol-defined inclusion criteria may apply.
Exclusion Criteria
- Under 50 years.
- Other protocol-defined exclusion criteria may apply.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Anecortave Acetate Anecortave Acetate 15 mg sterile suspension Posterior juxtascleral injection in the study eye at 6 month intervals (Day 0, Month 6, Month 12, Month 18) Anecortave Acetate Vehicle Anecortave Acetate Vehicle Posterior juxtascleral injection in the study eye at 6 month intervals (Day 0, Month 6, Month 12, Month 18)
- Primary Outcome Measures
Name Time Method Mean change from baseline in logMAR visual acuity score at 12 months Month 12
- Secondary Outcome Measures
Name Time Method